Registry of Acute Coronary Syndromes in Ferrara
Official title: Acute coRonary sYndrOmes proSpective regisTry Of Ferrara
Run by University Hospital of Ferrara · NCT02438085 · Data updated 2026-11-12
This study is collecting information about how patients with acute coronary syndromes are treated in Ferrara, Italy, to better understand their care and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | University Hospital of Ferrara Academic / other |
| Locations | 1 site (Cona, Ferrara) |
| Status | Recruiting |
| Started | June 2014 |
| Main results expected | November 30, 2028 |
| Study ends | November 30, 2032 |
| Registry record updated | November 14, 2023 |
| Trial ID | NCT02438085 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old who are residents of the Ferrara area and are admitted to the hospital for acute coronary syndromes.
✕Probably not a fit
Patients who are not residents of the Ferrara area or those under 18 years old will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to describe the clinical epidemiology and management of acute coronary syndromes (ACS) in Ferrara, Italy. It will collect data on patients admitted to hospitals in the area who receive coronary artery angiography and percutaneous coronary intervention (PCI). The study will gather information on patient characteristics, clinical management, biomarkers, procedural details, and long-term outcomes. The University Hospital of Ferrara serves as the hub center for this initiative, ensuring a high volume of ACS cases for comprehensive analysis.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of ACS management and improve patient outcomes in the Ferrara region.
How similar studies have gone: Other similar registries have shown success in improving clinical outcomes and understanding of acute coronary syndromes, indicating that this approach is well-established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>18 years * hospital admission for acute coronary syndromes * resident in the Ferrara area Exclusion Criteria: * none
Where it's running
-
University Hospital of Ferrara
Cona, Ferrara, Italy Recruiting
Study contacts
- Study coordinator: Veronica Lodolini, BSc
- Email: veronica.lodolini@student.unife.it
- Phone: +390532236450
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
Early Triple Lipid-Lowering Therapy After ACS
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Early single antiplatelet therapy after IVUS-guided PCI in ACS
This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.
-
Local and systemic macrophage activation in coronary and peripheral artery disease
This study tests whether macrophage activity inside coronary and peripheral arteries relates to circulating monocyte subtypes in people with stable and acute artery disease.
-
Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty
This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.